| Literature DB >> 32504292 |
Hamid Reza Aghayan1, Moloud Payab2, Fereshteh Mohamadi-Jahani3, Seyed Sajjad Aghayan4, Bagher Larijani5, Babak Arjmand6,7.
Abstract
Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.Entities:
Keywords: Cell culture; Cell therapy; Clinical application; GMP; Mesenchymal stem cells; Placenta
Year: 2021 PMID: 32504292 DOI: 10.1007/7651_2020_282
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745